The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer

Sponsor
The Second Affiliated Hospital of Shandong First Medical University
Study ID
NCT06092242
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

To evaluate the efficacy and safety of TAS-102 combined with bevacizumab as first-line therapy in patients with advanced colorectal cancer who could not tolerate or did not receive combined chemotherapy

Key Dates

First listed
Oct 23, 2023
Start date
Oct 15, 2023
Status verified
Oct 2023
Primary completion
Oct 15, 2025
Completion
Oct 15, 2027

Study Design

Enrollment
50 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: TAS-102 combined with bevacizumab

Primary Outcome Measure

Progression Free Survival [ Time Frame: 2 years ]

Central Contacts

Related Studies